Achieve Life Sciences (ACHV) Stock Price, News & Analysis

Company Overview

Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company focused on developing and commercializing cytisinicline, an investigational therapy designed to help adults stop smoking and address nicotine dependence. The company is listed on the Nasdaq Capital Market under the symbol ACHV.

Cytisinicline is a plant-derived small molecule that acts on neuronal nicotinic acetylcholine receptors involved in nicotine addiction. Achieve is evaluating the therapy in clinical studies for smoking cessation and potential support for quitting other forms of nicotine use. The company’s development programs have included the ORCA series of clinical trials conducted in the United States.

Achieve’s principal activities center on clinical development, regulatory preparation and potential commercialization of cytisinicline. Because the therapy remains an investigational product unless and until it receives applicable regulatory approvals, its availability and approved uses may change as development and regulatory review progress.

Key Stats

• Today's Range: $7.80 to $8.09
• 50-Day Range: $5.96 to $8.53
• 52-Week Range: $2.62 to $8.64
• Volume: 2.83 million shs
• Average Volume: 1.46 million shs
• Market Capitalization: $821.14 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $15.00
• Consensus Rating: Buy

Achieve Life Sciences Stock Analysis - MarketRank™

Achieve Life Sciences scored higher than 43% of companies evaluated by MarketBeat, and ranked 596th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Buy

Consensus Rating

Achieve Life Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 5 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Achieve Life Sciences has a consensus price target of $15.00, representing about 88.0% upside from its current price of $7.98.

Amount of Analyst Coverage

Achieve Life Sciences has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Achieve Life Sciences are expected to grow in the coming year, from ($0.91) to ($0.50) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Achieve Life Sciences is -5.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Achieve Life Sciences is -5.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Achieve Life Sciences has a P/B Ratio of 19.95. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

16.28% of the float of Achieve Life Sciences has been sold short.

Short Interest Ratio / Days to Cover

Achieve Life Sciences has a short interest ratio ("days to cover") of 12.19, which indicates bearish sentiment.

Change versus previous month

Short interest in Achieve Life Sciences has recently increased by 0.20%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Achieve Life Sciences does not currently pay a dividend.

Dividend Growth

Achieve Life Sciences does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Achieve Life Sciences this week, compared to 4 articles on an average week.

Search Interest

Only 9 people have searched for ACHV on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

4 people have added Achieve Life Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 1.2 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Achieve Life Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $175,115.00 in company stock.

Percentage Held by Insiders

1.80% of the stock of Achieve Life Sciences is held by insiders.

Percentage Held by Institutions

33.52% of the stock of Achieve Life Sciences is held by institutions.

Company Calendar

• Last Earnings: 8/11/2026
• Today: 9/19/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:ACHV
• CIK: 949858
• Web: achievelifesciences.com
• Phone: (425) 686-1500
• Fax: 425-686-1600
• Employees: 28
• Year Founded: 1995

Price Target and Rating

• Average Price Target for Achieve Life Sciences: $15.00
• High Price Target: $19.00
• Low Price Target: $12.00
• Potential Upside/Downside: +88.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.55)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$54.65 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -511.12%
• Return on Assets: -82.35%

Debt

• Debt-to-Equity Ratio: 0.87
• Current Ratio: 0.95
• Quick Ratio: 0.95

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.40 per share
• Price / Book: 19.95

Miscellaneous

• Outstanding Shares: 102,900,000
• Free Float: 101,050,000
• Market Cap: $821.14 million
• Optionable: Optionable
• Beta: 2.25